HSPA1A and colorectal carcinoma: In conclusion, this study demonstrated that a novel signature constructed by pairing IR-DEGs (HSPA1A and CCRL2) could predict the outcomes of patients with CRC and may help to distinguish those patients who might benefit from antitumor immunotherapy.